ORAL SEMAGLUTIDE VERSUS EMPAGLIFLOZIN, SITAGLIPTIN AND LIRAGLUTIDE IN THE UK: LONG-TERM COST-EFFECTIVENESS ANALYSES BASED ON THE PIONEER CLINICAL TRIAL PROGRAMME